These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 30756306)

  • 1. Use of Mortality as an Endpoint in Noninferiority Trials May Lead to Ethically Problematic Conclusions.
    Hersh AM; Walter RJ; Abberegg SK
    J Gen Intern Med; 2019 Apr; 34(4):618-623. PubMed ID: 30756306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empirical Consequences of Current Recommendations for the Design and Interpretation of Noninferiority Trials.
    Aberegg SK; Hersh AM; Samore MH
    J Gen Intern Med; 2018 Jan; 33(1):88-96. PubMed ID: 28875400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement.
    Piaggio G; Elbourne DR; Pocock SJ; Evans SJ; Altman DG;
    JAMA; 2012 Dec; 308(24):2594-604. PubMed ID: 23268518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protocol adherence rates in superiority and noninferiority randomized clinical trials published in high impact medical journals.
    Bamat NA; Ekhaguere OA; Zhang L; Flannery DD; Handley SC; Herrick HM; Ellenberg SS
    Clin Trials; 2020 Oct; 17(5):552-559. PubMed ID: 32666826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reporting of noninferiority and equivalence randomized trials for major prostaglandins: a systematic survey of the ophthalmology literature.
    Eyawo O; Lee CW; Rachlis B; Mills EJ
    Trials; 2008 Dec; 9():69. PubMed ID: 19055743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of reporting of noninferiority and equivalence randomized trials.
    Le Henanff A; Giraudeau B; Baron G; Ravaud P
    JAMA; 2006 Mar; 295(10):1147-51. PubMed ID: 16522835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COMPare: a prospective cohort study correcting and monitoring 58 misreported trials in real time.
    Goldacre B; Drysdale H; Dale A; Milosevic I; Slade E; Hartley P; Marston C; Powell-Smith A; Heneghan C; Mahtani KR
    Trials; 2019 Feb; 20(1):118. PubMed ID: 30760329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editorial policy and the reporting of randomized controlled trials: a survey of instructions for authors and assessment of trial reports in Indian medical journals (2004-05).
    Tharyan P; Premkumar TS; Mathew V; Barnabas JP; Manuelraj
    Natl Med J India; 2008; 21(2):62-8. PubMed ID: 18807310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noninferiority Clinical Trials: The Good, the Bad, and the Ugly.
    Lesaffre E
    Semin Liver Dis; 2018 May; 38(2):97-102. PubMed ID: 29871016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endorsement of the CONSORT guidelines, trial registration, and the quality of reporting randomised controlled trials in leading nursing journals: A cross-sectional analysis.
    Jull A; Aye PS
    Int J Nurs Stud; 2015 Jun; 52(6):1071-9. PubMed ID: 25540865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noninferiority Designed Cardiovascular Trials in Highest-Impact Journals.
    Bikdeli B; Welsh JW; Akram Y; Punnanithinont N; Lee I; Desai NR; Kaul S; Stone GW; Ross JS; Krumholz HM
    Circulation; 2019 Jul; 140(5):379-389. PubMed ID: 31177811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sample size for a noninferiority clinical trial with time-to-event data in the presence of competing risks.
    Han D; Chen Z; Hou Y
    J Biopharm Stat; 2018; 28(4):797-807. PubMed ID: 29157093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consistency ensured test strategies for supportive evidence of treatment efficacy in noninferiority clinical trials.
    Huque M; Valappil T; Alosh M
    J Biopharm Stat; 2018; 28(1):1-14. PubMed ID: 29173026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and Validation of a Natural Language Processing Tool to Generate the CONSORT Reporting Checklist for Randomized Clinical Trials.
    Wang F; Schilsky RL; Page D; Califf RM; Cheung K; Wang X; Pang H
    JAMA Netw Open; 2020 Oct; 3(10):e2014661. PubMed ID: 33030549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noninferiority trials with nonadherence to the assigned randomized treatment.
    Korn EL; Gray RJ; Freidlin B
    Clin Trials; 2019 Dec; 16(6):673-681. PubMed ID: 31409130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preliminary evidence on the uptake, use and benefits of the CONSORT-PRO extension.
    Mercieca-Bebber R; Rouette J; Calvert M; King MT; McLeod L; Holch P; Palmer MJ; Brundage M;
    Qual Life Res; 2017 Jun; 26(6):1427-1437. PubMed ID: 28168602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Completeness of reporting in abstracts of randomized controlled trials in subscription and open access journals: cross-sectional study.
    Jerčić Martinić-Cezar I; Marušić A
    Trials; 2019 Dec; 20(1):669. PubMed ID: 31791393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-arm noninferiority trials with a prespecified margin for inference of the difference in the proportions of binary endpoints.
    Hida E; Tango T
    J Biopharm Stat; 2013; 23(4):774-89. PubMed ID: 23799810
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.